Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject

D. C. Mohr, A. C. Boudewyn, W. Likosky, E. Levine, D. E. Goodkin

Research output: Contribution to journalArticlepeer-review

139 Scopus citations

Abstract

The management of many chronic illnesses involves medications that must be injected on a frequent basis. With fewer support resources available, patients are increasingly being obliged to manage injectable medications themselves. Interferon beta-1a (IFNβ-1a), recommended for the treatment of multiple sclerosis (MS), must be injected intramuscularly on a weekly basis. Patients are generally advised and taught to self-inject, if possible. This longitudinal study examined cognitive and affective contributions to the ability to self-inject and adherence to IFNβ-1a over 6 months following initiation of medication. Participants were 101 patients with a relapsing form of MS. Injection self-efficacy expectations, injection anxiety, adherence expectations, method of injection administration, and 6-month adherence to IFNβ-1a were fitted to a path analytic model. Pretreatment injection self-efficacy expectations were significantly related to 6-month adherence. This relation was mediated by the patient's ability to self-inject. Patients' experienced level of injection anxiety was related to adherence but not to method of injection.

Original languageEnglish (US)
Pages (from-to)125-132
Number of pages8
JournalAnnals of Behavioral Medicine
Volume23
Issue number2
DOIs
StatePublished - Jan 1 2001

ASJC Scopus subject areas

  • Psychology(all)
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject'. Together they form a unique fingerprint.

Cite this